Published in Vaccine Weekly, May 14th, 2003
The announcement, made at the British Society for Colposcopy & Cervical Pathology (BSCCP) meeting in Manchester on April 12, 2003, relates to a study carried out on 29 patients at three centers in the U.K. Early results indicate that a prime boost strategy, using a combination of Xenova's TA-CIN and TA-HPV candidate therapeutic vaccines, is both safe and well tolerated and has demonstrated clear clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly